The CereVasc eShunt™ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus
Location: United States, Massachusetts, Newton
Employees: 11-50
Total raised: $114M
Founded date: 2013
Investors 2
| Date | Name | Website |
| 02.11.2022 | Xontogeny | xontogeny.... |
| 04.10.2024 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.05.2024 | Series B | $70M | - |
| 10.06.2020 | Series A | $44M | - |
Mentions in press and media 12
| Date | Title | Description |
| 16.07.2024 | CereVasc Announces Appointments of New Directors | Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of Directors BOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, toda... |
| 13.05.2024 | CereVasc Raises $70M in Series B Financing | CereVasc, a Boston, MA-based clinical-stage, medical device company, raised $70M in Series B funding. The round was led by Bain Capital Life Sciences and existing investor Perceptive Xontogeny Venture Fund (PXV), with additional participati... |
| 07.05.2024 | CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephalus | With this FDA IDE approval, CereVasc will initiate the STRIDE pivotal study. BOSTON, May 7, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced today... |
| 10.06.2020 | CereVasc Closes $43.9M Series A Financing | CereVasc, Inc., a Boston, MA-based company focused on improving the treatment of patients with hydrocephalus, closed an expanded Series A financing that raised a total of $43.9m. The round was led by the Perceptive Xontogeny Venture (PXV) F... |
| 09.06.2020 | CereVasc Announces Closing of $43.9 Million Series A Financing | CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the closing of an expanded Series A financing that raised a total of $43.9 million led by the Perceptive Xontogeny Venture (PXV) Fu... |
| 09.06.2020 | CereVasc closes $44 million Series A round to treat 'water on the brain' | CereVasc, an Auburndale-based biotech focused on treating hydrocephalus, closed its Series A round of $43.9 million led by the Perceptive Xontogeny Venture Fund and ATON Partners. Hydrocephalus, often referred to as "water on the brain... |
| 09.06.2020 | CereVasc nets $43M to test minimally invasive hydrocephalus procedure | The developers of a minimally invasive implant for treating hydrocephalus have raised $43.9 million to help launch first-in-human clinical testing. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central ... |
| 09.06.2020 | CereVasc Closes $43.9 Million Series A | BOSTON--(BUSINESS WIRE)--CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the closing of an expanded Series A financing that raised a total of $43.9 million led by the Perceptive X... |
| 09.06.2020 | CereVasc Closes $43.9 Million Series A | BOSTON--(BUSINESS WIRE)--CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the closing of an expanded Series A financing that raised a total of $43.9 million led by the Perceptive X... |
| 09.06.2020 | CereVasc Announces Closing of $43.9 Million Series A Financing | – Proceeds to fund clinical trials of the eShunt™ System for treatment of hydrocephalus – – Series A financing led by the Perceptive Xontogeny Venture Fund – BOSTON–(BUSINESS WIRE)–June 9, 2020– CereVasc, Inc., a company focused on improvin... |
Show more